ArticleThe Journal of biological chemistry2012
A proteasome inhibitor-stimulated Nrf1 protein-dependent compensatory increase in proteasome subunit gene expression reduces polycomb group protein level.
Article in The Journal of biological chemistry, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 28 citations in OpenAlex.
- Bioinformatic Analysis Reveals the Association of Human N-Terminal Acetyltransferase Complexes with Distinct Transcriptional and Post-Transcriptional Processes.Biochemical genetics · 2025Article
- NF-E2-related factor 1 suppresses the expression of a spermine oxidase and the production of highly reactive acrolein.Scientific reports · 2025Article
- The proteasome as a drug target for treatment of parasitic diseases.Advances in parasitology · 2024Review
- Calmodulin inhibition as a mode of action of antifungal imidazole pharmaceuticals in non-target organisms.Toxicology research · 2020Article
- Combination cisplatin and sulforaphane treatment reduces proliferation, invasion, and tumor formation in epidermal squamous cell carcinoma.Molecular carcinogenesis · 2018Article
- A Simple Light Isotope Metabolic Labeling (SLIM-labeling) Strategy: A Powerful Tool to Address the Dynamics of Proteome VariationsMolecular & cellular proteomics : MCP · 2017Article
- Anabolic and Antiresorptive Modulation of Bone Homeostasis by the Epigenetic Modulator Sulforaphane, a Naturally Occurring Isothiocyanate.The Journal of biological chemistry · 2016Article
- Epigenetic regulation of Keap1-Nrf2 signaling.Free radical biology & medicine · 2015Review
- The selective post-translational processing of transcription factor Nrf1 yields distinct isoforms that dictate its ability to differentially regulate gene expression.Scientific reports · 2015Article
- BMI-1, a promising therapeutic target for human cancer.Oncology letters · 2015Article
- Survival of skin cancer stem cells requires the Ezh2 polycomb group protein.Carcinogenesis · 2015Article
- Article
- Nrf2, a regulator of the proteasome, controls self-renewal and pluripotency in human embryonic stem cells.Stem cells (Dayton, Ohio) · 2014Article
- MG132, a proteasome inhibitor, enhances LDL uptake in HepG2 cells in vitro by regulating LDLR and PCSK9 expression.Acta pharmacologica Sinica · 2014Article
- Newborn mouse lens proteome and its alteration by lysine 6 mutant ubiquitin.Journal of proteome research · 2014Article
- Divergent tissue and sex effects of rapamycin on the proteasome-chaperone network of old mice.Frontiers in molecular neuroscience · 2014Article
- The Bmi-1/NF-κB/VEGF story: another hint for proteasome involvement in glioma angiogenesis?Journal of cell communication and signaling · 2013Article
- Epigenetic cancer prevention mechanisms in skin cancer.The AAPS journal · 2013Review
- Identification of a population of epidermal squamous cell carcinoma cells with enhanced potential for tumor formation.PloS one · 2013Article
- Developmental expression of the Nfe2-related factor (Nrf) transcription factor family in the zebrafish, Danio rerio.PloS one · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
The polycomb group (PcG) proteins, Bmi-1 and Ezh2, are important epigenetic regulators that enhance skin cancer cell survival. We recently showed that Bmi-1 and Ezh2 protein level is reduced by treatment with the dietary chemopreventive agents, sulforaphane and green tea polyphenol, and that this reduction involves ubiquitination of Bmi-1 and Ezh2, suggesting a key role of the proteasome. In the present study, we observe a surprising outcome that Bmi-1 and Ezh2 levels are reduced by treatment with the proteasome inhibitor, MG132. We show that this is associated with a compensatory increase in the level of mRNA encoding proteasome protein subunits in response to MG132 treatment and an increase in proteasome activity. The increase in proteasome subunit level is associated with increased Nrf1 and Nrf2 level. Moreover, knockdown of Nrf1 attenuates the MG132-dependent increase in proteasome subunit expression and restores Bmi-1 and Ezh2 expression. The MG132-dependent loss of Bmi-1 and Ezh2 is associated with reduced cell proliferation, accumulation of cells in G(2), and increased apoptosis. These effects are attenuated by forced expression of Bmi-1, suggesting that PcG proteins, consistent with a prosurvival action, may antagonize the action of MG132. These studies describe a compensatory Nrf1-dependent, and to a lesser extent Nrf2-dependent, increase in proteasome subunit level in proteasome inhibitor-treated cells and confirm that PcG protein levels are regulated by proteasome activity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.